Identification of Potential FDA-Approved Inhibitors of SARS-CoV-2 Helicase Through a Multistep In silico Approach: A Promising Prospect for COVID-19 Treatment
Based on our analyses, we identified nine compounds with promising potential as SARS-CoV-2 helicase inhibitors, namely aniracetam, aspirin, chromocarb, cinnamic acid, lawsone, loxoprofen, phenylglyoxylic acid, and antineoplaston A10. The findings of this research help the scientific community to further investigate these compounds, both <i>in vitro</i> and <i>in vivo</i>.
Authors
- Ibrahim H. Eissa (ORCID: https://orcid.org/0000-0002-6955-2263)
- Alaa Elwan (ORCID: https://orcid.org/0000-0003-4270-616X)
- Aisha A. Alsfouk (ORCID: https://orcid.org/0000-0003-4497-5013)
- Eslam B. Elkaeed (ORCID: https://orcid.org/0000-0002-2546-8035)
- Ahmed M. Metwaly (ORCID: https://orcid.org/0000-0001-8566-1980)
Institutions
- Princess Nourah bint Abdulrahman University (SA)
- Alfaisal University (SA)
- Al-Azhar University (EG)
Publication Details
- Journal
- Medicinal Chemistry
- Published
- 2024-11-29
- DOI
- https://doi.org/10.2174/0115734064318640241112071225
- Citations
- 1
- Primary Topic
- Computational Drug Discovery Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.36
Funders
- Princess Nourah Bint Abdulrahman University